Literature DB >> 1336703

Cholinergic 'blockade' as a model of the cognitive deficits in Alzheimer's disease.

H Christensen1, N Maltby, A F Jorm, H Creasey, G A Broe.   

Abstract

The performance of 44 Alzheimer patients and 33 controls was examined on tests previously found to be differentially affected by scopolamine administration. Tests of secondary memory, performance intelligence, primary memory, semantic retrieval, procedural memory and verbal intelligence were included. It was found that Alzheimer patients performed more poorly than controls on tests of secondary memory, as measured by selective reminding, recall and recognition. Procedural memory, as measured by stem completion, homophone spelling and transformed text reading, did not differ between Alzheimer patients and controls. Semantic memory, verbal intelligence and primary memory were impaired in moderate and severe cases. However, patients with 'mild' dementia, as measured by the Mini-Mental State Examination, did not differ from controls on tests of semantic memory, verbal intelligence and primary memory. It was concluded that the pattern of anterograde memory deficits and preserved abilities in mild dementia mimicked that previously observed in scopolamine administration in young subjects.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1336703     DOI: 10.1093/brain/115.6.1681

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  12 in total

Review 1.  Memory assessment in studies of cognition-enhancing drugs for Alzheimer's disease.

Authors:  M Simard; R van Reekum
Journal:  Drugs Aging       Date:  1999-03       Impact factor: 3.923

2.  Cholinergic Grb2-Associated-Binding Protein 1 Regulates Cognitive Function.

Authors:  Nan-Nan Lu; Chao Tan; Ning-He Sun; Ling-Xiao Shao; Xiu-Xiu Liu; Yin-Ping Gao; Rong-Rong Tao; Quan Jiang; Cheng-Kun Wang; Ji-Yun Huang; Kui Zhao; Guang-Fa Wang; Zhi-Rong Liu; Kohji Fukunaga; Ying-Mei Lu; Feng Han
Journal:  Cereb Cortex       Date:  2018-07-01       Impact factor: 5.357

3.  Anticholinergic Amnesia is Mediated by Alterations in Human Network Connectivity Architecture.

Authors:  Jasmeer P Chhatwal; Aaron P Schultz; Trey Hedden; Brendon P Boot; Sarah Wigman; Dorene Rentz; Keith A Johnson; Reisa A Sperling
Journal:  Cereb Cortex       Date:  2019-07-22       Impact factor: 5.357

Review 4.  The significance of the cholinergic system in the brain during aging and in Alzheimer's disease.

Authors:  R Schliebs; T Arendt
Journal:  J Neural Transm (Vienna)       Date:  2006-10-13       Impact factor: 3.575

5.  Pharmacokinetic-pharmacodynamic relationships of central nervous system effects of scopolamine in healthy subjects.

Authors:  Marieke Liem-Moolenaar; Peter de Boer; Maarten Timmers; Rik C Schoemaker; J G Coen van Hasselt; Stephan Schmidt; Joop M A van Gerven
Journal:  Br J Clin Pharmacol       Date:  2011-06       Impact factor: 4.335

Review 6.  Modes and models of forebrain cholinergic neuromodulation of cognition.

Authors:  Michael E Hasselmo; Martin Sarter
Journal:  Neuropsychopharmacology       Date:  2010-07-28       Impact factor: 7.853

7.  Effects of chronic tramadol administration on cognitive flexibility in mice.

Authors:  Elpidio Attoh-Mensah; Marianne Léger; Gilles Loggia; Thomas Fréret; Chantal Chavoix; Pascale Schumann-Bard
Journal:  Psychopharmacology (Berl)       Date:  2021-06-25       Impact factor: 4.530

8.  Efficacy of tacrine and lecithin in mild to moderate Alzheimer's disease: double blind trial.

Authors:  N Maltby; G A Broe; H Creasey; A F Jorm; H Christensen; W S Brooks
Journal:  BMJ       Date:  1994-04-02

Review 9.  Neuronal mechanisms of the attentional dysfunctions in senile dementia and schizophrenia: two sides of the same coin?

Authors:  M Sarter
Journal:  Psychopharmacology (Berl)       Date:  1994-05       Impact factor: 4.530

Review 10.  Mechanisms of GABAergic and cholinergic neurotransmission in auditory thalamus: Impact of aging.

Authors:  B D Richardson; S Y Sottile; D M Caspary
Journal:  Hear Res       Date:  2020-06-11       Impact factor: 3.672

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.